Toxic epidermal necrolysis is a severe, life-threatening skin condition that requires immediate, specialized medical care to control symptoms, prevent dangerous complications, and support the body’s healing process.

Understanding the goals of treating a life-threatening skin condition

When someone develops toxic epidermal necrolysis, the primary goal is not necessarily to cure the condition with a single medication, but rather to keep the person alive while their body heals and their skin gradually regenerates. Treatment focuses on stopping the cause of the reaction, managing severe pain, preventing life-threatening infections, and maintaining vital body functions that become compromised when large areas of skin are lost. About 25% of people who develop this condition do not survive, which shows how crucial timely and appropriate treatment becomes.^[1]

The treatment approach depends heavily on how much of the body’s surface is affected and how quickly the condition progresses. Because toxic epidermal necrolysis involves more than 30% of the skin peeling away, the body loses its protective barrier against germs, loses fluids rapidly, and cannot regulate temperature normally. This makes the condition similar to severe burns, and treatment strategies often mirror those used in burn care. Medical teams must act quickly because the disease can progress within just three days.^[3]

There are established treatment protocols approved by medical institutions, but researchers continue to explore new therapies that might improve survival rates and reduce long-term complications. Some promising approaches are being tested in clinical settings, though no single treatment has been proven to definitively change the course of the disease once it begins.^[10]

Standard approaches to treating toxic epidermal necrolysis

The cornerstone of treating toxic epidermal necrolysis is immediate hospitalization, ideally in a specialized burn unit or intensive care unit. The first and most critical step is identifying and immediately stopping any medication that might have triggered the reaction. Studies have shown that when the suspected drug is withdrawn quickly—ideally on the same day blisters or skin erosions first appear—mortality can drop significantly, from 26% to 5%.^[10]

Supportive care, which means treatments that help the body function while it heals itself, forms the backbone of therapy. Patients are typically isolated to reduce the risk of infection, as their exposed skin provides an easy entry point for bacteria. The hospital room is often heated to a temperature between 25°C and 28°C because patients lose the ability to maintain their body temperature when so much skin is damaged.^[10]

Fluid replacement is essential because the loss of skin allows body fluids and salts to leak out, similar to what happens with severe burns. Patients receive fluids through a vein, and the amount is carefully monitored and adjusted based on central venous pressure and urine output. However, people with toxic epidermal necrolysis typically need less aggressive fluid replacement than burn patients because the damage to small blood vessels is less severe.^[10]

Wound care involves gently cleansing the affected skin and applying protective dressings. These dressings may be infused with petroleum jelly or medication to keep the damaged areas moist and protected. Medical teams use techniques borrowed from burn care, applying sterile coverings to minimize contamination and prevent evaporation of body fluids. The care team constantly monitors for signs of infection and administers antibiotics when necessary.^[11]

Pain management is crucial because the condition causes extreme discomfort, comparable to severe burns. Patients receive strong pain medications to make them as comfortable as possible. For pain in the mouth, which is often severely affected, doctors may prescribe a special mouthwash containing lidocaine, a numbing agent that provides temporary relief and makes eating and swallowing less painful.^[11]

Nutritional support becomes necessary when mouth and throat involvement makes eating difficult or impossible. In these cases, patients may receive nutrients through a feeding tube inserted through the nose and guided to the stomach, called a nasogastric tube. This ensures the body receives the energy and building blocks it needs for healing.^[11]

Eye care is vital because the condition often affects the eyes, potentially leading to permanent vision problems if not properly managed. An eye specialist, called an ophthalmologist, examines patients early and regularly throughout treatment. For mild eye symptoms, preservative-free artificial tears are applied at least four times daily. Eye drops containing corticosteroids may be used to control eye inflammation, though the overall use of corticosteroids in this condition remains debated.^[11]

Some patients need help breathing, especially when the airways become involved. In these situations, doctors may perform tests to evaluate the airway and keep it clear. In advanced cases, patients might require intubation, where a tube is placed in the windpipe, or mechanical ventilation, where a machine helps with breathing.^[11]

Medications used in standard treatment

Beyond supportive care, several medications may be used, though their effectiveness varies and remains somewhat controversial in the medical community. Antibiotics are given when signs of infection appear, not routinely, as the goal is to prevent resistance and only treat actual infections.^[12]

Intravenous immunoglobulin, often abbreviated as IVIG, is a treatment that involves giving antibodies collected from blood donors through a vein. The theory behind using IVIG is that it might block the harmful immune signals that cause skin cells to die. Some medical centers use this treatment, though controlled studies have not definitively proven its benefit.^[11]

The use of corticosteroids, which are powerful anti-inflammatory drugs, remains debated. Some doctors prescribe them early in the disease, believing they can dampen the excessive immune response. However, others worry that corticosteroids might increase infection risk or delay healing. Different institutions follow different protocols, and there is no universal agreement on their use.^[11]

Cyclosporine, a medication that suppresses the immune system, has been used in some cases. The rationale is that it might stop the immune attack on skin cells. Some treatment centers include cyclosporine in their protocols, but like other therapies, controlled trials are limited.^[13]

Antihistamines may be given to reduce itching and provide some relief from discomfort, though they do not alter the course of the disease.^[10]

Recovery typically takes several weeks to months. Skin usually regrows over two to three weeks, but most patients face a lengthy recovery period with possible long-term problems. These can include changes in skin color, chronic dryness of skin and mucous membranes, hair loss, abnormal nail growth, difficulty urinating, and genital abnormalities. Some patients develop chronic eye problems, including increased sensitivity to light and vision impairment.^[5]

Treatments being explored in clinical research

Because standard treatment does not actively reverse the disease process and survival rates remain concerning, researchers are actively investigating new therapies that might improve outcomes. These experimental treatments are based on growing understanding of what happens at the molecular level when toxic epidermal necrolysis develops.

Scientists have discovered that the condition involves an excessive immune response where certain immune cells, particularly CD8+ T cells, attack and kill skin cells. This understanding has led to investigation of therapies that target specific parts of this immune attack.^[13]

One area of research focuses on a protein called granulysin, which is released from cytotoxic T cells and natural killer cells. Studies have found that granulysin plays a key role in killing skin cells during toxic epidermal necrolysis, and the amount of granulysin in blister fluid correlates with how severe the disease becomes. Researchers are exploring ways to block granulysin or neutralize its effects, though these approaches are still in early research stages.^[13]

Another target is interleukin-15, a signaling molecule that has been found at increased levels in patients with toxic epidermal necrolysis. This molecule appears to increase production of granulysin, so blocking interleukin-15 might reduce the damage. Experimental therapies targeting this pathway are being studied, though they have not yet reached widespread clinical testing.^[13]

Research has also focused on Fas ligand, a protein that triggers cell death. The theory holds that interactions between Fas (a receptor on cell surfaces) and its ligand, particularly a soluble form released from certain immune cells, lead to skin cell death and blister formation. Some researchers are investigating ways to interrupt this pathway, though practical treatments based on this research are not yet available for routine use.^[13]

Tumor necrosis factor-alpha inhibitors, which are medications already used for other inflammatory conditions like rheumatoid arthritis, have been tried in some cases of toxic epidermal necrolysis. These drugs block a powerful inflammatory signal and might reduce the immune attack on skin cells. While some individual case reports suggest possible benefit, these medications have not undergone rigorous clinical trials for toxic epidermal necrolysis specifically.^[13]

Plasmapheresis, a procedure where blood is removed, filtered to remove certain components like antibodies or inflammatory molecules, and returned to the body, has been attempted in some medical centers. The idea is to physically remove harmful immune factors from the bloodstream. However, this approach requires specialized equipment and trained personnel, and evidence supporting its effectiveness remains limited.^[13]

Clinical trials investigating these and other approaches are ongoing, though they face significant challenges. Because toxic epidermal necrolysis is rare, affecting only about 1 to 2 people per million each year, it is difficult to gather enough patients to conduct large, well-controlled studies. Most evidence comes from small case series, individual hospital experiences, or observations from treatment centers rather than from randomized controlled trials that would provide stronger evidence.^[3]

Some research institutions are collecting data systematically to better understand which treatments work best. These efforts involve collaboration between burn centers, intensive care units, and dermatology departments across different countries. Researchers hope that by pooling information about treatment approaches and outcomes, they can identify which interventions truly improve survival and reduce complications.

Most common treatment methods

• Supportive care in specialized units
  • Hospitalization in burn units or intensive care units where staff have experience managing extensive skin loss
  • Isolation in heated rooms to prevent infection and maintain body temperature
  • Constant monitoring of vital signs and organ function
• Stopping the triggering medication
  • Immediate discontinuation of all suspected drugs, particularly those started in the past four weeks
  • Review of all medications to identify the most likely culprit
  • Documentation to prevent future exposure to the same drug or related medications
• Fluid and electrolyte management
  • Intravenous fluids tailored to individual needs based on the extent of skin involvement
  • Careful monitoring and adjustment based on urine output and central venous pressure
  • Typically requiring 3 to 4 liters daily for patients with 50% body surface area affected
• Wound and skin care
  • Gentle cleansing of affected areas using techniques similar to burn care
  • Application of protective dressings infused with petroleum jelly or medication
  • Sterile coverings to minimize contamination and evaporation
  • Regular assessment and care by trained wound specialists
• Pain control
  • Strong pain medications to manage severe discomfort comparable to serious burns
  • Special mouthwashes containing lidocaine for mouth and throat pain
  • Regular assessment and adjustment of pain medication to ensure patient comfort
• Infection prevention and treatment
  • Continuous monitoring for signs of infection in exposed skin areas
  • Antibiotics given when actual infection develops, not routinely
  • Cultures taken from skin, blood, and mucous membranes to identify specific bacteria
• Nutritional support
  • Feeding through a nasogastric tube when mouth involvement prevents normal eating
  • Provision of adequate calories and nutrients to support healing
  • Transition to normal eating as mouth and throat heal
• Eye care
  • Regular examination by ophthalmologists throughout hospital stay
  • Preservative-free artificial tears applied at least four times daily
  • Corticosteroid eye drops if significant inflammation develops
  • Daily cleaning of eyelids and lubrication to prevent permanent damage
• Respiratory support
  • Assessment and monitoring of airways when throat or lung involvement occurs
  • Oxygen supplementation by face mask as needed
  • Intubation or mechanical ventilation in severe cases
• Immunomodulatory therapies
  • Intravenous immunoglobulin (IVIG) given in some medical centers
  • Corticosteroids used in some protocols, particularly when started early
  • Cyclosporine tried in select cases at specialized centers
  • Tumor necrosis factor-alpha inhibitors used experimentally in some institutions